| ΔEffectivenessa | ΔCostb | Cost per case of event prevented (ICER) | ||
---|---|---|---|---|---|
NNTc | Third-party payer perspective | Healthcare sector perspective | Third-party payer perspective | Healthcare sector perspective | |
Base-case analysis (ITT scenario for effectiveness estimation + cost measured from the index date until the end of observation) | |||||
 All-cause death | 56.63 | 969 | − 342 | 54,851 | − 19,391 |
 Hospitalized hypoglycemia | 30.06 | 969 | − 342 | 29,115 | − 10,293 |
1st sensitivity analysis (ITT scenario for effectiveness estimation + cost measured from the index date until the occurrence of study event) | |||||
 All-cause death | 56.63 | 971 | − 325 | 55,002 | − 18,425 |
 Hospitalized hypoglycemia | 30.06 | 1128 | 47 | 33,901 | 1399 |
2nd sensitivity analysis (AT scenario for effectiveness estimation + cost measured from the index date until the end of observation) | |||||
 All-cause death | 100.80 | 969 | − 342 | 97,633 | − 34,515 |
 Hospitalized hypoglycemia | 29.79 | 969 | − 342 | 28,856 | − 10,201 |
3rd sensitivity analysis (AT scenario for effectiveness estimation + cost measured from the index date until the occurrence of study event) | |||||
 All-cause death | 100.80 | 971 | − 325 | 97,901 | − 32,796 |
 Hospitalized hypoglycemia | 29.79 | 1128 | 47 | 33,600 | 1387 |